All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Addition of CBM588 to Cabozantinib/Nivolumab Shows Potential in Metastatic RCC

March 3rd 2025

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

Roswell Park Awards $50,000 in Community Impact Grants for Local Cancer-Focused Projects

March 3rd 2025

5 WNY organizations received funding to advance cancer prevention, early detection, and patient support from Roswell Park Comprehensive Cancer Center.

CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC

March 3rd 2025

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

Rusfertide Meets Response End Point in Phlebotomy-Dependent Polycythemia Vera

March 3rd 2025

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

T-DXd Improves OS in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

March 3rd 2025

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

Prognostic vs Predictive Factors in Oncology Carry Differing Intent but May Have Complementary Clinical Utility

March 3rd 2025

Maurie Markman, MD, discusses the differences between prognostic vs predictive factors and their clinical utility in oncology practice.

TNBC Awareness Day Emphasizes Progress in Treatment Strategies

March 3rd 2025

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

Revisit Every OncLive On Air Episode From February 2025

March 3rd 2025

Read a recap of the episodes of OncLive On Air that aired in February 2025.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Retrospective Data Show Potential Safety of Enfortumab Vedotin in Older Patients With Urothelial Carcinoma

March 2nd 2025

A retrospective study revealed that enfortumab vedotin did not produce excessive toxicity in older patients with urothelial carcinoma.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Analyses Show Effects of Treatment, Patient Location on HRQOL in Bladder and Prostate Cancer

March 1st 2025

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025

March 1st 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Fox Chase Cancer Center, Temple Health Study Reveals Timely Treatment Is Critical for Rectal Cancer Survival

February 28th 2025

Starting treatment within 60 days of initial evaluation significantly improves survival rates for patients with rectal cancer.

CHMP Recommends Subcutaneous Daratumumab Plus VRd for Newly Diagnosed Myeloma

February 28th 2025

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

CHMP Recommends Approval of Glofitamab Plus Chemotherapy for R/R DLBCL

February 28th 2025

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

February 28th 2025

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

CHMP Recommends Conditional Approval of Linvoseltamab for R/R Multiple Myeloma

February 28th 2025

The CHMP has issued a positive opinion for linvoseltamab in relapsed/refractory multiple myeloma.

T-DXd Receives Positive CHMP Opinion for HER2-Low or HER2-Ultralow Metastatic Breast Cancer

February 28th 2025

The CHMP has recommended the approval of trastuzumab deruxtecan for HER2-low or HER2-ultralow metastatic breast cancer.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.